Venous thromboembolism (VTE) is a leading cause of morbidity and mortality worldwide.
Appropriate anticoagulation is crucial in the treatment and prevention of recurrent VTE …

The pharmacokinetics of oral rivaroxaban are highly predictable and only affected to a
limited extent by bodyweight; therefore, dose adjustments for bodyweight are not required …

Essentials• The optimal dosing strategy of rivaroxaban for patients at the extremes of body
weight is not known.• A pharmacokinetic study was conducted based in real‐world patients …

Background: Obesity is a well-known risk factor for venous thromboembolism (VTE),
however, obese patients are under-represented in clinical trials (1; 2). Four direct oral …

Background There is scarce evidence on the effectiveness and safety of recommended-
dose direct acting oral anticoagulants (DOACs) in obese patients with venous …

Background Direct oral anticoagulants (DOAC) use remains challenging in obese patients
treated for Venous-Thrombo-Embolism (VTE) due to the paucity of prospective and …

There is limited data evaluating clinical outcomes of rivaroxaban versus warfarin in obese
patients with venous thromboembolism (VTE). Our objective was to evaluate the …

Abstract Abstract 20 Harry R. Büller, MD, PhD on behalf of the EINSTEIN Investigators.
Background The EINSTEIN DVT and EINSTEIN PE studies showed that a fixed-dose …

Background Rivaroxaban is a first-line option for the management of venous
thromboembolism (VTE). However, limited data are available regarding its effectiveness in …

Background Polypharmacy, including use of inhibitors of CYP3A4 and P‐glycoprotein (P‐
gp), is common in patients with venous thromboembolism (VTE) and is associated with …